Table of Contents
What changed
Revenue fell 9.4% to $175.7m and EBITDA dropped to $18.2m from $34.0m. Profit before tax declined 60.4% to $11.0m and NPAT fell 60.8% to $7.9m, with the effective tax rate broadly stable (28.7% vs 28.1%). Ingredient margin softened 90bps to 48.4%, which management attributed to diseconomies of scale on lower volumes.
The balance sheet moved decisively. Cash fell from $5.9m to $0.15m, gross borrowings rose from $3.4m to $15.4m, and the group moved from a $2.5m net cash position to $15.3m of net debt (~0.84x EBITDA). Equity declined 13.3% to $58.0m and total liabilities rose 30.5% to $50.6m. Operating cash flow fell 67% to $9.8m, while capex rose to $7.7m from $2.9m, leaving pre-lease free cash flow of just $2.0m versus $26.7m in FY22. No FY23 final dividend was indicated in the supplied data, versus a 4.0c final in FY22.
What matters
- Earnings quality deteriorated across the P&L, cash flow and balance sheet in parallel. NPAT fell in line with PBT (no tax distortion), cash conversion to EBITDA collapsed from 86.9% to 53.6%, and the group shifted from net cash to net debt – this is a coherent, not isolated, weakening.
- Capex stepped up sharply into a declining revenue base. Capex rose to 4.4% of revenue from 1.5%, absorbing most of the reduced operating cash flow. Pre-lease FCF/NPAT fell from 133.2% to 25.6%, meaning reported earnings were materially under-supported by cash.
- Return on equity halved to 13.5% from 29.9%, and the absence of a final dividend (versus 4.0c prior) is consistent with the liquidity position – cash of $0.15m leaves no buffer without drawing on the bank facility.
Expectations
No quantified FY24 guidance, medium-term target or forward-work metric was disclosed in the supplied excerpts, so the release cannot be assessed against a stated shape. What the HY23 context does support is that FY23 was first-half weighted: H1 delivered 53.7% of revenue, 63.2% of EBITDA and 74.9% of NPAT. Implied second-half NPAT was only $2.0m on $81.3m of revenue, a materially weaker exit rate than the reported full-year averages suggest. Any read-through to FY24 therefore starts from a lower run-rate than the headline numbers imply.
Quality of result
The result is lower quality than the headline NPAT of $7.9m suggests. Cash conversion deteriorated materially – a point worth flagging directly – with OCF/EBITDA falling more than 30 percentage points. Working capital was not the driver (inventory days eased to 8.7 from 9.7; receivable days remained negligible), so the OCF shortfall reflects genuine trading weakness rather than a timing reversal that will unwind. The increase in borrowings of $12.0m broadly funded the combined shortfall in operating cash, the step-up in capex, and prior-period distributions. EBITDA is a non-GAAP measure and no full statutory bridge was provided in the supplied materials. There were no disclosed non-recurring items to normalise against.
Unresolved
- What drove the H2 step-down in profitability specifically – was it further volume loss, promotional intensity, or cost that has since been removed via the referenced cost-reduction initiatives?
- What are the covenants, maturity and headroom on the $15.4m of gross borrowings, given cash of $0.15m?
- What is the FY24 capex trajectory, and was FY23's $7.7m a one-off catch-up or the new baseline?
- Is the dividend formally suspended, or simply deferred, and against what coverage policy?
- What subscriber/order volume metrics underlie the 9.4% revenue decline, and have they stabilised post year-end?
This briefing cannot assess underlying customer/order trends, covenant headroom, or FY24 trading direction, as none were disclosed in the supplied materials.
Key metrics
| Metric | FY23 | FY22 | Change |
|---|---|---|---|
| Revenue | $175.7m | $194.0m | -9.4% ↓ |
| EBITDA | $18.2b | — | — |
| Net profit after tax | $7.8m | $20.0m | -60.8% ↓ |
| Net cash inflow from operating activities | $9.8m | $29.5m | -67.0% ↓ |
| Final dividend per share | — | 4.0c | — |
| Profit before tax | $11.0m | $27.8m | -60.4% ↓ |
| Cash and cash equivalents | $0.1m | $5.9m | -97.5% ↓ |
| Total assets | $108.6m | $105.7m | +2.7% ↑ |
Reference: annolyse.ai/briefings/mfb-fy23
Analytical metrics
| Metric | FY23 | FY22 | Context |
|---|---|---|---|
| PBT growth | -60.4% | — | — |
| Effective tax rate | 28.7% | 28.1% | — |
| OCF / EBITDA (cash conversion) | 53.6% | 86.9% | deteriorated |
| FCF pre-lease | $2.0m | $26.7m | −$24.6m |
| FCF / NPAT | 25.6% | 133.2% | complementary conversion metric |
| Capex % revenue | 4.4% | 1.5% | — |
| Capex | $7.7m | −$2.9m | +$10.6m |
| Debtor days | 0.7 | 0.4 | +0.3 days |
| Inventory days | 8.7 | 9.7 | -1.0 days |
| Trade debtors | $0.4m | $0.2m | +$0.1m |
| Net debt | $15.3m | −$2.5m | +$17.8m |
| Net debt / EBITDA | 0.84x | -0.07x | Weakening |
| Gross borrowings | $15.4m | $3.4m | +$12.0m |
| Payout ratio vs NPAT | 0.0% | — | — |
| Payout ratio vs FCF pre-lease | 0.0% | — | covered |
| ROE (annualised) | 13.5% | 29.9% | Weakening |
| HY23 share of FY23 revenue | 53.7% | — | Other half was 46.3% |
| HY23 share of FY23 EBITDA | 63.2% | — | Other half was 36.8% |
| HY23 share of FY23 NPAT | 74.9% | — | Other half was 25.1% |
| Profit from continuing operations | $7.8m | $20.0m | −$12.2m |
Reference: annolyse.ai/briefings/mfb-fy23
This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.